A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

September 17, 2026 updated by: Jiangsu HengRui Medicine Co., Ltd.

A Domestic, Prospective, Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

2022

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Anhui
      • Chizhou, Anhui, China, 247000
        • The People's Hospital of Chizhou
    • Guangdong
      • Shantou, Guangdong, China, 515041
        • First Affiliated Hospital of Shantou University Medical College
      • Shenzhen, Guangdong, China, 518020
        • Shenzhen People's Hospital
    • Guangxi
      • Dongying, Guangxi, China, 257034
        • Shengli Oilfield Central Hospital
      • Nanning, Guangxi, China, 530021
        • The First Affiliated Hospital of Guangxi Medical University
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Zhongnan Hospital of Wuhan University
      • Wuhan, Hubei, China, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      • Wuhan, Hubei, China, 430014
        • Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology
    • Hunan
      • Changsha, Hunan, China, 410005
        • Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University
    • Jiangsu
      • Changshu, Jiangsu, China, 215500
        • Changshu No.2 People's Hospital (Affiliated Changshu Hospital of Nantong University)
      • Suqian, Jiangsu, China, 223800
        • Suqian People's Hospital of Nanjing Drum Tower Hospital Group
      • Suzhou, Jiangsu, China, 215600
        • Zhangjiagang First People's Hospital
    • Shandong
      • Binzhou, Shandong, China, 256600
        • Binzhou Medical University Hospital
      • Jinan, Shandong, China, 250012
        • Affiliated Hospital of Shandong University of Traditional Chinese Medicine
      • Linyi, Shandong, China, 276000
        • Linyi People's Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200011
        • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
    • Sichaun
      • Dazhou, Sichaun, China, 63500
        • Dazhou Central Hospital
    • Sichuan
      • Leshan, Sichuan, China, 614000
        • Leshan People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300100
        • Tianjin Nankai Hospital, Tianjin Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients receiving remazolam toluenesulfonate for painless gastroscopy and colonoscopy

Description

Inclusion Criteria:

  1. Use rebenin ® for painless gastroscopic sedation and painless colonoscopic sedation
  2. Patients need to sign informed consent

Exclusion Criteria:

  1. Patients who are participating in or planning to participate in any interventional clinical trial
  2. The investigator considers that there are any other reasons for the patient's ineligibility for the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cohort 1

Painless gastroscopic sedation cohort

Remimazolam Tosilate for Injection

Cohort 2

Painless colonoscopy sedation cohort

Remimazolam Tosilate for Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adverse events
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy

Use adverse event record form,Refer to version 5.0 of the NCI-CTCAE

Within 3 days of receiving gastroscopy and colonoscopy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serious adverse events
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy

Refer to SAE definition standards

Within 3 days of receiving gastroscopy and colonoscopy
Adverse drug reactions
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy

By evaluating the association of adverse events with drugs

Within 3 days of receiving gastroscopy and colonoscopy
Injection pain questionnaire
Time Frame: Within 3 days of receiving gastroscopy and colonoscopy

By observing and asking

Within 3 days of receiving gastroscopy and colonoscopy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2022

Primary Completion (Actual)

February 8, 2023

Study Completion (Actual)

February 8, 2023

Study Registration Dates

First Submitted

January 28, 2022

First Submitted That Met QC Criteria

February 23, 2022

First Posted (Actual)

February 24, 2022

Study Record Updates

Last Update Posted (Actual)

September 21, 2026

Last Update Submitted That Met QC Criteria

September 17, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ARMS

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe